首页>Immunopharmacology and immunotoxicology>Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up
Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up
作者单位：Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany[1]Department of Medical Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey[2]Antalya Training and Research Hospital, Department of Internal Medicine, Clinical Immunology and[3]Department of Otorhinolaryngology, Medical School, Dokuz Eylul University, Izmir, Turkey[4]
换一批
